围术期GLP-1受体激动剂与SGLT2抑制剂的继续使用策略
本文评论围术期GLP-1受体激动剂和SGLT2抑制剂的用药管理差异。作者主张围术期继续使用GLP-1受体激动剂,而SGLT2抑制剂仅在计划操作前一天停药,并讨论了监管机构建议分歧及在持续不确定性下的麻醉实践应对。
要点
- 围术期应继续使用GLP-1受体激动剂。
- SGLT2抑制剂仅在计划操作前一天停药。
- 监管机构建议存在差异,需在不确定性中权衡。
核心结论
- GLP-1受体激动剂应在围术期继续使用。
- SGLT2抑制剂仅应在计划操作前一天停用。
主要发现
- 不同药品监管机构与组织对GLP-1受体激动剂和SGLT2抑制剂的围术期管理建议存在差异。
- 继续使用这些药物可避免可变速率静脉胰岛素输注的危害,同时提供血糖控制。
临床怎么用
- 麻醉医师面对监管建议分歧和持续不确定性时,应参考本文主张的继续GLP-1受体激动剂、操作前一天停SGLT2抑制剂的策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Type 2 diabetes mellitus is an increasingly common long-term condition, and suboptimal perioperative glycaemic control can lead to postoperative harms. The advent of new antidiabetic drugs, in particular glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter 2 (SGLT2) inhibitors, has enabled perioperative continuation of these medicines, thus avoiding the harms of variable rate i.v. insulin infusions whilst providing glycaemic control. There are differences between medicines regulatory agencies and organisations on how these classes that are most often used to treat diabetes mellitus, (but also in the case of SGLT2 inhibitors chronic kidney disease and heart failure in those without diabetes) should be managed in the perioperative period. In this commentary, we argue that GLP-1 receptor agonists should continue during the perioperative period and that SGLT2 inhibitors should only be omitted the day prior to a planned procedure . The reasons for the differing advice advocated between regulatory agencies and what anaesthetic practitioners should do in the face of continuing uncertainty are discussed.
引用
- Dhatariya K, Levy N, Russon K, et al. Perioperative use of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for diabetes mellitus. Br J Anaesth. 2024. PMID: 38290906. doi:10.1016/j.bja.2023.12.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。